Commons Sense

Hansard-based summaries and metrics

<-- Back to proposed bills

Correction to PQ53263 and PQ53380

28 April 2022

Proposing MP
Maria Caulfield Con
Lewes
Type
Written Ministerial Statement
Department
Department of Health and Social Care
View on Parliament.uk -->

At a Glance

Issue Summary

The statement corrects inaccuracies in previous written answers regarding the availability of radioligand therapy for NHS patients.

Action Requested

The minister clarifies that Lutetium (177Lu) oxodotreotide is licensed and funded by the NHS, treating the expected number of patients as recommended by NICE. Additionally, guidance on Lu vipivotide tetraxetan for prostate cancer treatment is being developed with final guidance due to be published on 23 November 2022.

Key Facts

  • Radioligand therapy Lutetium (177Lu) oxodotreotide is licensed and funded by the NHS.
  • NICE Technology appraisal guidance TA539 recommends Lutetium for treating unresectable or metastatic neuroendocrine tumours, published on 29 August 2018.
  • Final guidance on Lu vipivotide tetraxetan for prostate cancer treatment is expected to be published by NICE on 23 November 2022.
▸ Assessment & feedback
Summary accuracy